Skip to content

RCT to study the effect of intraosseous infusion of Tranexamic acid for the bleeding control during primary TKA

RCT to study the effect of intraosseous infusion of Tranexamic acid for the bleeding control during primary TKA

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200066293
Enrollment
Unknown
Registered
2022-11-30
Start date
2022-12-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

knee osteoarthritis

Interventions

Total knee arthroplasty group 1:intraosseous infusion TXA
Total knee arthroplasty group 2:intravenous TXA
Total knee arthroplasty group 3:intraosseous infusion TXA + intravenous TXA

Sponsors

orthopaedic department, Peking Union Medical College Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Patients with primary unilateral total knee arthroplasty; (2) Age >= 20 years old, < 80 years old, gender is not limited; (3) Patients who use aspirin and/or other antiplatelet medication before operation need to stop aspirin for more than 1 week; (4) The subjects gave informed consent and signed the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Allergy to tranexamic acid; (2) Patients with high risk of thrombosis, including previous VTE history, previous myocardial infarction patients, cerebral infarction patients, patients with malignant tumors, and patients with hypercoagulability, are known to be prone to thrombosis. (3) Complicated with other serious organ diseases such as heart, brain, lung, kidney and blood;. (4) Before operation, Hb was less than 11g/L. (5) He received major orthopedic surgery within three weeks before the operation. (6) At present, patients with diseases that have received anticoagulation therapy and patients who have received regular anticoagulation therapy in the past are combined.

Design outcomes

Primary

MeasureTime frame
total blood loss;

Secondary

MeasureTime frame
symptomatic venous thrombosis embolism;

Countries

China

Contacts

Public ContactFeng Bin

Peking Union Medical College Hospital

pumcfeng@163.com+86 13810487811

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026